Sandoz Agrees To Shelve Plans For Generic Zetia

Law360, New York (September 9, 2013, 7:24 PM EDT) -- Generic-drug maker Sandoz Inc. on Monday agreed not to make, sell or distribute a version of Merck & Co. Inc.’s anti-cholesterol drug Zetia until 2017, putting to rest Merck’s patent infringement suit.

Sandoz and its affiliates Sandoz AG, Sandoz International GmbH, Eon Labs Inc., Oriel Therapeutics Inc., Falcon Pharmaceuticals Inc., Lek Pharmaceuticals d.d. and Fougera Pharmaceuticals Inc. are all subject to the settlement, which was approved by U.S. District Judge Jose Linares.

“Except as and to the extent permitted by the settlement agreement, Sandoz, including any...
To view the full article, register now.